Public Health Infrastructure & Governance

Public-health infrastructure in PA-3 is the institutional environment in which every other D2 sub-domain operates. The federal architecture rests on Public Health Service Act §§ 247b ([PHEP](/paul/campaign/empower/glossary/#phep) cooperative agreements), 247d ([PHE](/paul/campaign/empower/glossary/#phe) declaration authority), and 317 (immunization program), plus ACA Title IV § 4002 establishing the [Prevention and Public Health Fund](/paul/campaign/empower/glossary/#pphf). The state architecture rests on the Pennsylvania Disease Prevention and Control Law of 1955 and 28 Pa. Code Title 28. The local architecture rests on Philadelphia Code Title 6 and the Home Rule Charter, with PDPH operating as a directly-funded CDC jurisdiction in parallel to PA DOH. Three federal-disruption patterns dominate the verification window: capacity erosion through the FDA reduction in force (approximately 18% of FDA workforce; approximately 25% HHS aggregate with voluntary separations) and the CDC Immunization Services Division termination (August 2025; excluded from the August 12, 2025 narrowing of the Rhode Island injunction); governance disruption through [ACIP](/paul/campaign/empower/glossary/#acip) charter renewal (April 9, 2026) and the separate Decision Memo schedule reduction (January 5, 2026) — the reconstituted ACIP membership and the schedule reduction are both stayed by the Murphy preliminary injunction (March 16, 2026); and federalism stress through PPHF cumulative rescissions of approximately $11.85 billion FY13-FY27, with FY26 elimination proposed in the Trump budget.

Legal Architecture

Constitutional foundation

Federal public-health authority rests on the Spending Clause (U.S. Const. Art. I § 8, cl. 1), which authorizes conditional federal grants to states and localities for public-health programs. The 10th Amendment locates the underlying police power for public-health regulation with the states; federal authority operates through conditional spending and through interstate-commerce-grounded statutes. The 14th Amendment equal protection clause grounds the civil-rights overlays on federally-funded public-health programs (Title VI; Section 504). Pennsylvania's Const. Art. III § 14 (general welfare framing) and Article IV (executive branch authority for the Department of Health) ground state public-health authority.

Federal statutory layer

Public Health Service Act § 247b, 42 U.S.C. § 247b — Public Health Emergency Preparedness (PHEP) cooperative agreements. CDC issues PHEP cooperative agreements to 50 states plus four directly-funded localities, including Philadelphia. Statutory stability: HIGH; administrative vulnerability: MODERATE — funding mechanism stable but appropriated levels and sub-grantee structure variable.

PHSA § 247d, 42 U.S.C. § 247d — Public Health Emergency declaration authority. Authorizes the Secretary of Health and Human Services to declare a public-health emergency, triggering supplemental authorities and resources. Statutory stability: HIGH; administrative vulnerability: MODERATE — declaration authority is Secretary-discretionary.

PHSA § 317, 42 U.S.C. § 247b — federal immunization program supporting state and local vaccination infrastructure. Operates through the Advisory Committee on Immunization Practices (ACIP) recommendation pathway and the Vaccines for Children Program. Statutory stability: HIGH; administrative vulnerability: HIGH — appropriated levels are variable; the ACIP recommendation pathway is administratively variable.

ACA Title IV § 4002 — Prevention and Public Health Fund (PPHF), 42 U.S.C. § 300u-11. Permanent annual mandatory appropriation through 2027 ($2.0 billion per year) and onward, dedicated to prevention and public health programs. Statutory stability: HIGH for the authorizing statute itself; administrative vulnerability: HIGH — Congressional rescissions have repeatedly redirected the appropriation. Cumulative PPHF rescissions FY13-FY27 are approximately $11.85 billion, with specific rescissions across P.L. 112-96 ($6.25B), P.L. 114-255 ($3.5B), P.L. 115-96 ($750M), and P.L. 115-123 ($1.35B). FY26 elimination is a Trump budget proposal pending Congressional action. PPHF contributed approximately 13% of CDC's FY24 budget; FY24 transfers included $681.93 million to the CDC Immunization Program and $160 million to the Preventive Health Block Grant.

Federal agency layer — three patterns of disruption

The HHS-CDC-FDA institutional environment has been substantially restructured during the verification window. Three patterns of disruption are operative.

Pattern 1 — Capacity erosion via reduction in force. On April 1, 2025, HHS sent RIF notices to approximately 10,000 employees, of whom approximately 3,500 were FDA employees (approximately 18% of FDA's workforce). The Center for Devices and Radiological Health lost approximately 250 staff (approximately 11% of its 2,260 starting headcount), with about 30 later called back. Total HHS reduction reaches approximately 25% when approximately 10,000 voluntary separations are added. The April 1 RIFs were initially halted by Judge Susan Illston's preliminary injunction (N.D. Cal., May 2025); SCOTUS stayed the Illston injunction on July 8, 2025; HHS finalized terminations on July 14, 2025 for employees not covered by the surviving Rhode Island injunction. State of Rhode Island v. Trump (D.R.I., Judge Melissa DuBose, on appeal as No. 26-1070, 1st Cir.) was originally entered July 2025 and narrowed August 12, 2025 to cover FDA's Center for Tobacco Products, most CDC offices (with CDC's Immunization Services Division and Partnership and Vaccine Equity Branch excluded — those were terminated), HHS Office of Head Start, and HHS Office of the Assistant Secretary for Planning and Evaluation. CBER Director Peter Marks resigned March 27, 2025, citing in his protest letter to Acting Commissioner Sara Brenner that "truth and transparency are not desired by the Secretary"; his successor Vinay Prasad also resigned amid political pressure (per PharmExec, February 2026), evidencing continued CBER leadership churn.

Pattern 2 — Governance disruption via ACIP reconstitution and charter renewal. Two distinct events compose this pattern. First, the January 5, 2026 CDC Decision Memo signed by then-Acting CDC Director Jim O'Neill demoted seven vaccines (rotavirus, meningococcal, hepatitis A, hepatitis B, influenza, COVID-19, RSV) from universal recommendation to "shared clinical decision making" status. Second, the April 9, 2026 ACIP charter renewal broadened committee scope to include "vaccine safety research gaps," "cumulative effects" of childhood vaccines, aluminum adjuvants, "novel vaccine platforms such as mRNA," and foreign-country schedule comparisons, and added non-voting liaison members from vaccine-skeptic organizations (Independent Medical Alliance; Physicians for Informed Consent; Association of American Physicians and Surgeons). The Murphy preliminary injunction issued March 16, 2026 in American Academy of Pediatrics et al. v. Kennedy et al. (D. Mass.; Judge Brian E. Murphy; on appeal to the First Circuit) stays the Decision Memo, blocks the reconstituted ACIP membership (only 6 of 15 had meaningful vaccine expertise per the court's FACA analysis), invalidates three ACIP votes including the December 2025 hep B birth-dose downgrade, and overturns the May 2025 Secretarial Directive halting COVID-19 vaccine recommendations for pregnant women and healthy children. The pre-January 2026 federal childhood schedule is effectively restored. ACIP cannot meet under current conditions.

Pattern 3 — Federalism stress via funding-mechanism mismatch and rescission. The PPHF's structural feature — that the authorizing statute provides permanent appropriations but Congressional appropriators repeatedly redirect or rescind those appropriations to offset other priorities — is the canonical authorizing-statute / appropriated-funding mismatch case. Trump's FY26 budget proposal includes complete PPHF elimination; the final FY26 appropriation status is pending Congressional action.

State statutory layer

Pennsylvania Disease Prevention and Control Law of 1955, 35 P.S. §§ 521.1-521.21. The framework Pennsylvania public-health statute. Statutory stability: HIGH; administrative vulnerability: MODERATE — implementation regulations at 28 Pa. Code Title 28 are administratively set; the PA Code is current through 56 Pa.B. 778 (January 31, 2026).

State agency layer

Pennsylvania Department of Health (PA DOH). Administers the disease-prevention and control framework statewide. PA DOH operates the federal-state interface for the PHSA architecture and the PA implementation of immunization, communicable-disease, maternal-child, and chronic-disease programming. Pennsylvania has not announced a divergent-position posture post-Murphy; the question of state divergence on the childhood schedule is currently moot while the Murphy injunction holds and the pre-January 2026 federal schedule is restored.

Local statutory and local agency layer

Philadelphia Code Title 6 (the city health code) and the Philadelphia Home Rule Charter provide the local governance authority for the Philadelphia Department of Public Health (PDPH). PDPH operates as a directly-funded CDC jurisdiction in parallel with PA DOH for several federal funding streams — notably the PDPH HIV Prevention Cooperative Agreement (direct CDC funding). PDPH receives PHEP/ELC sub-grantee allocations within the federal funding architecture. Local administrative vulnerability: MODERATE — PDPH FY26 budget actuals are partially unverified.

Cross-cutting structural features

Feature 1 — Federalism stress as a structural feature. The pattern that authorizing statutes provide permanent or quasi-permanent appropriations while Congressional appropriators repeatedly redirect or rescind those appropriations is operative across multiple federal public-health funding streams — PPHF here, plus PHEP/ELC, Title V (treated in the Maternal & Child Health sub-domain), and FQHC § 330 Community Health Center Fund (treated in the Health Access sub-domain).

Feature 2 — Aggressive rollback under court constraint. The federal posture is not pure rollback but rollback constrained by court-imposed checks: Murphy on the vaccine schedule and ACIP reconstitution; Rhode Island on FDA CTP and most CDC offices; Braidwood (treated in the Communicable Disease and Chronic Disease sub-domains) preserving the ACA § 2713 preventive services mandate. The court-imposed checks have preserved statutory promises but have not restored institutional capacity that has been terminated outright (CDC ISD; EPA EJ offices; the BARDA mRNA contract base).

Feature 3 — State and local divergence patterns. Where federal architecture is rolling back, states and localities are diverging from the federal default in selective areas: state-AG litigation coalitions (Massachusetts in the AAP v. Kennedy plaintiff slate; the 19-state coalition in State of RI v. Trump; the 15-state coalition led by Minnesota AG Ellison parallel-suing on the Decision Memo); state-administered substitute infrastructure (16+ states have state-level EJ mapping tools as EJScreen substitutes — Maryland, Massachusetts, Minnesota among them); state-scale naloxone distribution programs (PA Overdose Prevention Program; treated in the Substance Use sub-domain). Pennsylvania remains operationally aligned with federal default in vaccine policy and is not a state-AG coalition leader on schedule litigation.

Constituent profiles

These profiles illustrate the structural features above. The pathways are drawn from current law applied to documented PA-3 conditions; the people are composites with no claim to identifiable individuals.

Profile 1: North Philadelphia family in the CDC ISD-supported immunization-equity zone

Constituent type: a household with one or more school-age children residing in a North/Northwest Philadelphia Core census tract, with parental hesitancy or scheduling difficulty around routine childhood immunization. The school-entry immunization compliance check has surfaced an immunization gap.

Pathway through the institutional system. The family historically would have been engaged by PDPH outreach work supported by federal CDC ISD and Partnership and Vaccine Equity Branch capacity-building. That federal-layer support was terminated in August 2025 following the Rhode Island injunction's narrowing — the August 12, 2025 order excluded CDC ISD from injunction protection. PDPH absorbs the capacity loss with its own outreach infrastructure. The family's school-entry compliance is governed by 28 Pa. Code § 23.83; the underlying immunization is recommended on the post-Murphy-restored pre-January 2026 federal childhood schedule.

Outcome. School-entry compliance pathway operates; outreach engagement that historically supported family decision-making is structurally degraded; the family proceeds without the federal-support-augmented engagement work.

Profile 2: West Philadelphia family seeking VFC vaccine access through PDPH

Constituent type: a low-income PA-3 household residing in a West Philadelphia Core tract, with one or more children eligible for the federal Vaccines for Children Program (Medicaid-enrolled, uninsured, or American Indian / Alaska Native). The household's pediatric provider attempts to administer a routine childhood vaccine to the household child through VFC.

Pathway through the institutional system. VFC was authorized through the National Childhood Vaccine Injury Act of 1986 and is funded through PHSA § 317. The CDC Immunization Program receives PPHF transfers; FY24 PPHF transfer to the CDC Immunization Program was $681.93 million. FY26 PPHF status is partially unverified, with elimination proposed in the Trump FY26 budget. The household's VFC access is statutorily protected, but the program's federal-funding pipeline carries near-term uncertainty.

Outcome. The household receives the VFC vaccine. Multi-year uncertainty about funding stability is the operative concern at the policy level.

Profile 3: PA-3 community in a PHEP-funded emergency-preparedness scenario

Constituent type: a PA-3 community broadly across Philadelphia tracts experiences an emergency-preparedness scenario — an infectious disease outbreak, an environmental incident, or a mass-casualty event. PDPH emergency response is activated.

Pathway through the institutional system. PDPH emergency response capacity is funded substantially through CDC PHEP cooperative agreements (PHSA § 247b). FY26 PHEP/ELC PA and Philadelphia direct allocations are partially unverified at the sub-domain level. PDPH FY26 budget actuals are also unverified.

Outcome. Emergency response operates within current PDPH capacity; multi-year exposure to PHEP funding fluctuation is the operative concern.

Conversational note

The institutional architecture that delivers public-health infrastructure to PA-3 residents is, in 2026, in the most active period of restructuring it has experienced in a generation. The headline events of the verification window — the FDA reduction in force; the firing and reconstitution of the Advisory Committee on Immunization Practices; the CDC Decision Memo demoting seven childhood vaccines; the wave of executive orders rolling back environmental justice; the closure of EPA EJ offices in all ten regions; the wind-down of mRNA vaccine development under BARDA — read as a coordinated rollback. The operative pattern is more nuanced. Each of these aggressive moves has met a court check. The Murphy injunction in the District of Massachusetts effectively restored the pre-January 2026 federal childhood vaccine schedule. The Rhode Island injunction protected the FDA Center for Tobacco Products and most of the CDC. The Supreme Court in Kennedy v. Braidwood upheld the ACA preventive-services mandate. The IRA Medicare Drug Price Negotiation Program continues under the Trump administration with Round 1 effective January 1, 2026 and Round 3 in progress. The federal posture is best described not as rollback alone but as aggressive rollback under court constraint plus selective preservation under political pragmatism.

For PA-3 residents, what this means in operational terms is that the federal-layer instruments of public health continue to function, often after substantial litigation, with two important qualifications. First, the institutional capacity that historically supported state-level public-health work — the CDC Immunization Services Division and Partnership and Vaccine Equity Branch; the EPA Office of Environmental Justice and External Civil Rights and its Region III office; the FDA staff carrying out routine drug-and-device review work — has in many cases been reduced or terminated outright. The court-imposed checks did not always extend to these structural capacities; the Rhode Island injunction's August 12, 2025 narrowing specifically excluded CDC ISD from protection. Second, the funding architecture sits within multi-year exposure. The PPHF has been progressively rescinded across four laws to a cumulative approximately $11.85 billion; FY26 elimination is on the table. The FQHC § 330 mandatory funding has been extended only through December 2026, with multi-year reauthorization deferred.

What this also means is that the role of state and local public-health institutions — PA DOH, PDPH, the regional partners — has become structurally more important. PDPH operates the immunization-program local interface that, until August 2025, was supported by federal CDC ISD capacity. PDPH's emergency preparedness operates through PHEP cooperative agreements whose FY26 levels are unverified. The Pennsylvania Disease Prevention and Control Law of 1955 and the 28 Pa. Code Title 28 framework continue operative. Pennsylvania has not announced a divergent state posture post-Murphy, which means the state continues to align with federal default — which, post-injunction, is the pre-January 2026 schedule. The structural pattern is that PA-3 residents inherit a federal architecture under court check and a state-and-local layer that is operationally stable but increasingly exposed if federal capacity continues to erode.

Geography & representation

Data provenance. PPHF cumulative rescissions FY13-FY27 ≈ $11.85 billion (NACo + ASTHO + CRS R47895 cumulative). FDA RIF total approximately 3,500 (approximately 18% of FDA workforce); CDRH approximately 250 (approximately 11% of 2,260 starting headcount); approximately 30 called back; total HHS reduction approximately 25% with voluntary separations (HHS estimate). The Rhode Island injunction State of Rhode Island v. Trump (D.R.I., Judge Melissa DuBose, on appeal as No. 26-1070, 1st Cir.) was originally July 2025 and narrowed August 12, 2025. The Murphy preliminary injunction in American Academy of Pediatrics et al. v. Kennedy et al. (D. Mass., Judge Brian E. Murphy) was issued March 16, 2026; HHS appealed to the First Circuit. The January 5, 2026 CDC Decision Memo and April 9, 2026 ACIP charter renewal are documented in CDC and Federal Register filings. PPHF FY26 specific appropriation, PHEP/ELC FY26 levels, and PDPH FY26 budget actuals are flagged for institutional-source retrieval.

PA-3 statistical profile. PA-3 residents are served by federal-state-local public-health infrastructure at multiple touchpoints — PHEP-funded emergency preparedness (PDPH); § 317-funded immunization (with VFC access for Medicaid-enrolled and uninsured children); PPHF-supported CDC programs (the CDC Immunization Program received $681.93 million in PPHF transfer in FY24 alone); and PDPH-administered communicable disease surveillance under 28 Pa. Code § 27. The number of PA-3 residents directly served by each federal funding stream is not disaggregated at the sub-domain level.

Geographic variation.

North/Northwest Philadelphia Core. Heaviest concentration of PA-3 residents who would historically have been served by CDC ISD-supported immunization equity work that has been terminated. PDPH MCFH division and the PDPH Immunization Program operate the local administrative interface for vaccine access; the federal-layer support previously available through CDC ISD is structurally degraded.
West Philadelphia Core. Represents a substantial share of PA-3 Medicaid-eligible adult population; FQHC pathways (treated in the Health Access sub-domain) are the primary access points; PHEP-related emergency preparedness flows through PDPH at the city level rather than via tract-specific funding flows.
Northwest Philadelphia. PHEP-supported emergency preparedness operates through PDPH city-level structures; tract-level disaggregation of preparedness investment is not part of the verification cycle's data set.
South/Southwest Philadelphia. Same city-level pattern; tract-level disaggregation requires PDPH district-by-program reporting that was not located in the verification cycle.

District-by-tract disaggregation of federal public-health funding flows is not available at the sub-domain level; sub-area variation is presented as structural inference from PDPH district reporting and the geographic concentration of disadvantaged populations established at the project frame.

Pathway tracing.

PHEP cooperative agreement funding flow. CDC issues PHEP cooperative agreements to 50 states plus four directly-funded localities (including Philadelphia). PA DOH receives state allocation; PDPH receives Philadelphia direct allocation. Sub-grantees flow at state and county level. Pathway breakdown points: FY26 appropriations level uncertain; PPHF transfer interaction historically supplemented PHEP base appropriation with FY26 PPHF status pending; sub-grantee performance and reporting compliance.
PPHF appropriations-mismatch mechanism. ACA § 4002 provides permanent annual mandatory appropriation through 2027 ($2.0 billion per year) and onward; Congressional appropriators have rescinded approximately $11.85 billion cumulative FY13-FY27 through omnibus or separate rescission legislation. Pathway breakdown points: FY26 elimination proposed with final status pending; downstream programs (CDC Immunization Program; Preventive Health Block Grant) affected proportionally to cumulative reduction.
ACIP recommendation → VFC eligibility → state implementation. ACIP recommends vaccines; CDC Director adopts; VFC and private insurance coverage typically follow. Pathway breakdown points: the Murphy injunction blocks the reconstituted ACIP from meeting, suspending the recommendation pathway for vaccines awaiting recommendation (Moderna mRNA flu; Pfizer/Valneva Lyme; RSV vaccines for adults 18-49); PA implementation references ACIP recommendations through 28 Pa. Code Chapter 23 Subchapter C but operates without divergent posture; the First Circuit appeal could alter the pathway.
Rhode Island injunction → CDC ISD termination → state-level immunization equity capacity. The CDC Immunization Services Division and Partnership and Vaccine Equity Branch supported state-level efforts to improve immunization rates in hesitant populations. The August 12, 2025 narrowing excluded CDC ISD from protection; ISD and PVEB were terminated. Federal capacity for state-level immunization equity support is no longer present. Pathway breakdown points: state-level immunization equity work in PA depends on PA DOH and PDPH absorption of capacity loss without federal support; the First Circuit appeal of the Rhode Island injunction could further reshape.

Representation question. The PHSA, ACA, and state/local framework promises PA-3 residents a federal infrastructure for public-health emergency preparedness, immunization, and prevention that is institutionally stable, professionally staffed (FDA; CDC; HHS), governed by science-informed advisory bodies (ACIP), and not subject to capricious reorganization. As of mid-2026, PA-3 constituents face a federal layer where the FDA workforce has been reduced by approximately 18% and several CDC offices have been terminated; CDC ISD and PVEB were terminated August 2025; ACIP cannot meet under current conditions following the Murphy injunction; PPHF cumulative rescissions reach approximately $11.85 billion with FY26 elimination proposed; FQHC § 330 funding extended only through December 2026. The state and local layer continues operative without divergent posture; PDPH absorbs the federal-capacity loss for immunization equity work; emergency preparedness funding has FY26 uncertainty. Two mechanisms account for the gap: the federalism-stress mechanism (authorizing statutes provide stable promises but appropriations and administrative capacity are administratively variable and have been progressively reduced) and the MAHA-era institutional restructuring (Trump executive orders plus Secretary Kennedy actions reducing FDA/CDC/HHS workforce, reconstituting ACIP, redirecting BARDA/mRNA work). The court-constraint element preserves the most aggressive elements (Murphy stays the schedule reduction; Braidwood preserves the preventive-services mandate) but does not fully restore the lost institutional capacity. The litigation pathway has been the operative check on the most aggressive rollback elements, but litigation does not restore institutional capacity that has been terminated outright. For PA-3, this is the primary federalism-stress finding at the public-health infrastructure layer.

Gap analysis

Gap 1 — PPHF authorizing-statute / appropriated-funding mismatch (G2-SD1-01). The Prevention and Public Health Fund's structural feature — that the authorizing statute provides permanent appropriations through 2027 ($2.0 billion per year) and onward but Congressional appropriators repeatedly redirect or rescind those appropriations to offset other priorities — is the canonical authorizing-statute / appropriated-funding mismatch case. Cumulative PPHF rescissions FY13-FY27 reach approximately $11.85 billion. FY26 elimination is a Trump budget proposal pending Congressional action. PPHF contributed approximately 13% of CDC's FY24 budget, with $681.93 million flowing to the CDC Immunization Program and $160 million to the Preventive Health Block Grant in FY24 alone.

Gap 2 — Capacity erosion via FDA RIF and CDC ISD termination (G2-SD1-02). Approximately 3,500 FDA employees (approximately 18% of the workforce) were RIF'd effective July 14, 2025 after the SCOTUS stay of the Illston preliminary injunction. CDRH lost approximately 250 (approximately 11% of 2,260 starting headcount; about 30 called back). The Rhode Island injunction protected most CDC offices but its August 12, 2025 narrowing excluded the CDC Immunization Services Division and Partnership and Vaccine Equity Branch, which were terminated. CBER leadership churn continues with Director Marks's resignation March 27, 2025 and successor Prasad's subsequent resignation (per PharmExec, February 2026). Total HHS reduction reaches approximately 25% when voluntary separations are added.

Gap 3 — PHEP/ELC operational reliance with FY26 uncertainty (G2-SD1-03). PDPH emergency-preparedness capacity is funded substantially through CDC PHEP cooperative agreements; the FY26 specific PA allocation is unverified at the sub-domain level. The structural reliance on the federal PHEP funding stream means that any FY26 reduction translates into PDPH emergency-response capacity directly.

Gap 4 — PA Disease Prevention and Control Law operational structure (G2-SD1-04). The Pennsylvania Disease Prevention and Control Law of 1955 (35 P.S. §§ 521.1-521.21) plus 28 Pa. Code Title 28 provide a stable state framework. The framework operates without divergent state posture from the federal default; the structural question is whether the state layer can absorb federal capacity loss without divergent posture, given Pennsylvania's non-leadership position in the state-AG litigation coalitions challenging federal rollback.

Gap 5 — Data infrastructure rollback via USDA ERS termination (G2-SD1-05). The USDA Economic Research Service terminations affect public-health-adjacent data infrastructure for food access, nutrition, and health-disparity reporting. Cross-reference to D4 Food, Drug & Device verified cycle for the substantive analysis.

Gap 6 — Governance disruption via ACIP charter rewrite and Decision Memo (G2-SD1-06). The April 9, 2026 charter renewal broadens ACIP scope into vaccine-skeptic territory (cumulative effects; aluminum adjuvants; mRNA platforms; foreign-country schedule comparisons) and adds non-voting liaison members from vaccine-skeptic organizations. The January 5, 2026 Decision Memo demoted seven vaccines from universal recommendation to "shared clinical decision making" status. The Murphy preliminary injunction stays the Decision Memo, blocks the reconstituted ACIP membership (only 6 of 15 had meaningful vaccine expertise per the court's FACA analysis), invalidates three ACIP votes including the December 2025 hep B birth-dose downgrade, and overturns the May 2025 Secretarial Directive halting COVID-19 vaccine recommendations for pregnant women and healthy children. HHS appealed to the First Circuit; appeal pending. Net status: charter rewrite operative; ACIP cannot function with current membership.